Cat. No.: HY-N6739

Beauvericin

고객리뷰

Based on 1 Customer Validation

Beauvericin is a cyclohexapeptide Fusarium toxin with insecticidal, antibacterial, anticancer, antiviral and cytotoxic activities. Beauvericin causes cellular genotoxicity by producing DNA breaks, chromosomal aberrations and micronuclei, and inhibits the PI3K/AKT pathway to induce apoptosis, thereby inhibiting the growth of HCC. In addition, Beauvericin affects immune function by inhibiting lymphocyte proliferation and interfering with the differentiation process of human monocytes into macrophages.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.97%
CAS No.: 26048-05-5
화학식: C₄₅H₅₇N₃O₉
분자량:783.95

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Beauvericin Chemical Structure

CAS No.: 26048-05-5

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
용액&용해도
- In Vitro
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

ACAT

All PI3K Isoforms :

All Akt Isoforms :

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC₅₀	1 μM Compound: 12	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay	[PMID: 36288556]
Huh-7	IC₅₀	4.3 μM Compound: 12	Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay	[PMID: 36288556]

In Vitro

Beauvericin (0-20 μM; 12, 24 and 36 h) has a strong antiproliferative activity against H22 hepatoma cells and promotes apoptosis of H22 hepatoma cells^[5].
Beauvericin (50 μM; 72 h) induces apoptosis in turkey peripheral mononuclear cells^[6].
Beauvericin (0.3-100 µM) reversibly inhibits L-type voltage-dependent Ca₂₊ current (I_Ca,L) in NG108-15 neuronal cells in a concentration-dependent manner with an IC₅₀ value of 4 µM^[7].
Beauvericin has IC₅₀ values of 1.0 µM, 2.9 µM, and 2.5 µM for immature dendritic cells, mature dendritic cells, and macrophages, respectively^[8].
Beauvericin (1.6 and 2.4 µM; 2 d) reduces CCR7 expression and increases IL-10 secretion in maturing dendritic cells^[8].
Beauvericin is a potent inhibitor of CYP3A1/2 in rat liver microsomes (IC₅₀=1.3 mM)^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[5]

Cell Line:

H22 liver cancer cells
Concentration:

0, 1, 3, 5,10,15 and 20 µM
Incubation Time:

12、24 and 36 h
Result:

Inhibited the growth of H22 cells in a dose-dependent manner.

Western Blot Analysis^[5]

Cell Line:

H22 liver cancer cells
Concentration:

0, 1, 3, 5,10,15 and 20 µM
Incubation Time:

12、24 and 36 h
Result:

Upregulated the Bax/Bcl-2 ratio and the levels of cleaved caspase-9 and cleaved caspase-3, and downregulated the p-PI3K/PI3K ratio and p-AKT/AKT ratio.

In Vivo

Beauvericin (5 mg/kg; i.p.; after the first dosing cycle, observe for two days and continue the second dosing cycle) reduces tumor volume and increases necrosis in allogeneic transplant model mice^[3].
Beauvericin (3, 5, 7 mg/kg; i.p.; once a week for three weeks) can significantly inhibit the growth of H22 allogeneic transplant model mice and increase the levels of TNF-α and IL-2 in mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c mice injected subcutaneously with mouse CT-26 colon cancer cells on the right side^[3]
Dosage:

5 mg/kg
Administration:

ntraperitoneal injection (i.p.)；The drug was administered on the third day after the injection of colon cancer cells and continued once a day for five days, then stopped for two days of observation, and continued on the tenth day after the injection of colon cancer cells, and continued once a day for four days.
Result:

Reduced the average tumor volume by 52.8 % and the average tumor weight by 60 %.

Animal Model:

Human cervical cancer KB-3-1 xenograft mouse model^[3]
Dosage:

5 mg/kg
Administration:

Intraperitoneal injection (i.p.)； The drug was administered once a day starting on the fifth day after cervical cancer injection for five days, followed by two days of observation. The drug was administered once a day starting on the twelfth day after cervical cancer cell injection for four days.
Result:

Reduced the average tumor volume by 31.3 % and the average tumor weight by 31.2 %.

Chemical Information

CAS No. 26048-05-5
Appearance Solid
분자량 783.95
화학식 C₄₅H₅₇N₃O₉
Color White to off-white
SMILES

CN([C@H](C(O[C@](C(N([C@H](C(O[C@@H]1C(C)C)=O)CC2=CC=CC=C2)C)=O)([H])C(C)C)=O)CC3=CC=CC=C3)C([C@H](OC([C@@H](N(C1=O)C)CC4=CC=CC=C4)=O)C(C)C)=O
Structure Classification
- Antibiotics
- Macrolide Antibiotics
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Fusarium proliferatum,F. semitectum, and F. subglutinans
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

용액&용해도

In Vitro:

DMSO : 100 mg/mL (127.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2756 mL

6.3780 mL

12.7559 mL

5 mM

0.2551 mL

1.2756 mL

2.5512 mL

10 mM

0.1276 mL

0.6378 mL

1.2756 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Mallebrera B, et al. In vitro mechanisms of Beauvericin toxicity: A review[J]. Food and Chemical Toxicology, 2018, 111: 537-545. [Content Brief]

[2]. Wang Q, et al. Beauvericin, a bioactive compound produced by fungi: a short review[J]. Molecules, 2012, 17(3): 2367-2377. [Content Brief]

[3]. Heilos D, et al. The natural fungal metabolite beauvericin exerts anticancer activity in vivo: a pre-clinical pilot study[J]. Toxins, 2017, 9(9): 258. [Content Brief]

[4]. Maranghi F, et al. In vivo toxicity and genotoxicity of beauvericin and enniatins. Combined approach to study in vivo toxicity and genotoxicity of mycotoxins beauvericin (BEA) and enniatin B (ENNB)[J]. EFSA Supporting Publications, 2018, 15(5): 1406E.

[5]. Wang G, et al. Beauvericin exerts an anti-tumor effect on hepatocellular carcinoma by inducing PI3K/AKT-mediated apoptosis[J]. Archives of Biochemistry and Biophysics, 2023, 745: 109720. [Content Brief]

[6]. Dombrink-Kurtzman M A. Fumonisin and beauvericin induce apoptosis in turkey peripheral blood lymphocytes[J]. Mycopathologia, 2003, 156: 357-364. [Content Brief]

[7]. Wu S N, et al. Block of L-type Ca2+ current by beauvericin, a toxic cyclopeptide, in the NG108-15 neuronal cell line[J]. Chemical research in toxicology, 2002, 15(6): 854-860. [Content Brief]

[8]. Ficheux A S, et al. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: An in vitro study[J]. Toxicon, 2013, 71: 1-10. [Content Brief]

[9]. Mei L, et al. An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats[J]. Journal of enzyme inhibition and medicinal chemistry, 2009, 24(3): 753-762. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2756 mL	6.3780 mL	12.7559 mL	31.8898 mL
	5 mM	0.2551 mL	1.2756 mL	2.5512 mL	6.3780 mL
	10 mM	0.1276 mL	0.6378 mL	1.2756 mL	3.1890 mL
	15 mM	0.0850 mL	0.4252 mL	0.8504 mL	2.1260 mL
	20 mM	0.0638 mL	0.3189 mL	0.6378 mL	1.5945 mL
	25 mM	0.0510 mL	0.2551 mL	0.5102 mL	1.2756 mL
	30 mM	0.0425 mL	0.2126 mL	0.4252 mL	1.0630 mL
	40 mM	0.0319 mL	0.1594 mL	0.3189 mL	0.7972 mL
	50 mM	0.0255 mL	0.1276 mL	0.2551 mL	0.6378 mL
	60 mM	0.0213 mL	0.1063 mL	0.2126 mL	0.5315 mL
	80 mM	0.0159 mL	0.0797 mL	0.1594 mL	0.3986 mL
	100 mM	0.0128 mL	0.0638 mL	0.1276 mL	0.3189 mL

Keywords

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Beauvericin

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Biotoxin Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Fungal-Sourced Compound Library

Mass Spectrometry Natural Product Library

All PI3K Isoforms

All Akt Isoforms

All TNF Receptor Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table